ROARABLE
FREE $100K
My Trading Account β†’
β–Ύ
Trading Profile Active
Active Trader
Verified Trader
⚑ My $100K Trading Account β†’ β˜… My Saved Watchlist β†’
🟒 My $100K Account β†’ Today Screener Big Ideas Track Record πŸ’° $100K Arena 🎲 Predictions πŸ›οΈ Insiders 8 Analysts
Stock Ratings / Health Care / CUPR
CLGN (41) HSCS (38) LFWD (32) RGNT (31) ⌘ Pro Terminal β†’

Cuprina Holdings (Cayman) Limited (Class A) (CUPR) β€” RQD Stock Rating Cockpit

$1.84 +3.96% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $1.85

Cuprina Holdings (Cayman) Limited (Class A) (CUPR) carries a Roarable Rating of E (Strong Sell) with 21/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $13.5M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on CUPR Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is CUPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-03, Cuprina Holdings (Cayman) Limited (Class A) (NASDAQ: CUPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $1.84 (+3.96% 1D, market cap $13.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CUPR ranks #972 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does CUPR compare to CLGN and HSCS in the Health Care sector?
β–Ό

Within the Health Care sector (Industrial Specialties), CUPR carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of -1.3%, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and HSCS (HeartSciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $16.0M). Among the 5-stock peer group, CUPR leads on earnings multiple (N/A) while CUPR leads on capital efficiency (-35.0% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for CUPR?
β–Ό

Per CUPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001995704), Cuprina Holdings (Cayman) Limited (Class A) generated $38.8K in revenue (+9.2% YoY), -$3.6M in net income, and -$7.1M in free cash flow against $6.6M in total assets and $98.1K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $1.85 (+0.52%)🧬 Dilution Drag (+1.28% YoY Shares)βš™οΈ Cash Engine: 3/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (21/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-11.6% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510021
3-of-3 Quant Analysts Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR RQD RADARRw E Β· Rk E
Cash (3)Whales (3)SEC (3)Macro (10)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-16.8% Base Target
$16 Bull$2 Base$1 Bear
πŸ“¬ FREE CUPR RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for CUPR)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (21/100 Composite)
πŸ” WHY CUPR SCORES 21/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: Macro Regime Fit+10/20 pts (48% of score)

FRED Regime Γ— Technicals: 3% of 52W Range β€’ RSI-14 at 41.1 (NEUTRAL RANGE)

β–² #2 Bullish Driver: Cash Engine Quality+4/20 pts (19% of score)

SEC XBRL FY 2025 (10-K): 0% FCF Margin ($0 FCF) & 0% Gross Margin

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+1.28% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
29
Grade E$1.90+1.6% Next Q
Q2 (-2Q)
26
Grade E$1.93-4.1% Next Q
Q3 (-1Q)
24
Grade E$1.85-0.5% Next Q
Current
21
Grade E$1.84-11.6% Hist 90D Ξ±
Trajectory: E (29) β†’ E (21)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a CUPR Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While CUPR currently carries a cautious 21/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($2.26) and Max Pain ($1.93) forces dealer call-delta covering toward $15.54.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.28% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $CUPRβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œCUPR Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
YES 21%NO 79%Trade / Inspect Odds β†’
RSI-14 MOMENTUMNEUTRAL RANGE
41.130 Oversold Β· 70 Hot
ALTMAN-Z SHIELDDISTRESS RISK (<1.8)
0.36>3.0 Fortress Safe
PIOTROSKI F-SCOREWEAK QUALITY (1–4)
3 / 99-Pt Accounting
52-WEEK LASER RANGE3% OF RANGE
L: $1$1.84H: $15
1. Money & Cash Health● WEAK
Are profits real cash in the bank?

Weak cash conversion or heavy valuation strain compared to actual cash earned.

Factor Grade: ERQD 3 / 20
2. Big Money & Insiders● TRIMMING
Are whales & executives buying or selling?

Insiders and big institutional desks have been trimming shares rather than stepping up to buy.

Factor Grade: ERQD 6 / 40
3. Hidden Risks & Market Weather● WARNING
SEC fine-print scan & interest-rate fit

High sensitivity to tight interest rates or new risk warnings added to recent SEC annual filings.

Factor Grade: ERQD 12 / 40
MULTI-MODEL QUANT PANEL DELIBERATION

3-of-3 Quant Analysts Bearish Warning on CUPR

Cash & Moat Bull AI
ROIC & Free Cash Flow Model
BEARISH (15)

-35.0% ROIC with -1.3% gross margin and 2.80% FCF yield.

SEC Forensic Auditor AI
10-K Accruals & Altman-Z Guard
BEARISH (18)

Altman-Z 0.36 and Piotroski 3/9 pass balance-sheet audit.

Whale & Macro Hawk AI
Options Skew, 13F & Fed NetLiq
BEARISH (27)

6/40 institutional & smart-money positioning score with 10/20 macro alignment.

Bull Case: Why Buyers Like CUPR
  • βœ“Established market leader in Health Care with deep daily trading liquidity.
Bear Case: What Could Go Wrong
  • !Company executives have done more routine share selling than personal cash buying lately.
  • !Sensitive to high interest rates and tighter Federal Reserve market liquidity.
  • !Recent SEC filings added new risk-factor disclosures that warrant keeping an eye on margins.
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring CUPR)

  • βœ“Walkthrough of CUPR's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
CUPR // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.96%β–² RESISTANCE BREAKOUT
2026-11-03O $1.84H $1.84L $1.77C $1.84VOL 11.8K
RES: $1.09SUP: $0.37SMA50: $2.26SMA200: $3.00
$15.73$11.86$7.99$4.12$0.25RES $1.09SUP $0.37$1.842026-05-042026-06-172026-08-042026-09-182026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

CUPR Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ CUPR Butterfly Map β†’ + Track CUPR β†’
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
8.0%/yr Implied 5Y Growth

vs. +9.2% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on CUPR today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for CUPR. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for CUPR today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (CUPR)

Health Care Rank #972 of 1015 βš”οΈ CLGN vs CUPR Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (CUPR vs. CLGN, HSCS, LFWD, RGNT)

Industry: Industrial Specialties (55 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, Cuprina Holdings (Cayman) Limited (Class A) (CUPR) ranks #972 by composite RQD confidence (21/100, grade E) and #862 by equity capitalization ($13.5M). Within this direct 5-issuer industry benchmark cohort, CUPR leads on earnings valuation at N/A trailing P/E, while CUPR leads on capital efficiency and profitability with -35.0% ROIC and -1.3% gross margin. CLGN currently holds the highest overall quantitative score in the immediate peer group at 41/100 (D-) compared with CUPR at 21/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
CUPR ACTIVE
Cuprina Holdings (Cayman) Limited (Class A)
E 21/100 β€” -1.3% -35.0% +3.96% $13.5M Benchmark Subject
CLGN
CollPlant Biotechnologies Ltd
D- 41/100 β€” 64.8% -35.0% -1.33% $11.9M /clgn-vs-cupr β†’
HSCS
HeartSciences Inc.
D- 38/100 β€” 59.1% -35.0% -9.67% $16.0M /hscs-vs-cupr β†’
LFWD
Lifeward Ltd.
E 32/100 β€” 96.0% -35.0% +1.82% $16.9M /lfwd-vs-cupr β†’
RGNT
Regentis Biomaterials Ltd.
E 31/100 β€” β€” -35.0% 0.00% $9.6M /rgnt-vs-cupr β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2024–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001995704 β†—

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Cuprina Holdings (Cayman) Limited (Class A) (CUPR) reported GAAP revenue of $38.8K (+9.2% vs. FY2024 revenue of $35.5K ) , GAAP net income of -$3.6M, operating cash flow of -$7.1M, and free cash flow of -$7.1M (-672.8% YoY). On the balance sheet, CUPR closed FY2025 with $6.6M in total assets against $98.1K in total debt (Altman Z-Score: 0.36, Piotroski F-Score: 3/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $38.8K -$3.6M -$7.1M -$7.1M $6.6M $98.1K
FY2024 (FY) 2024-12-31 $35.5K -$1.1M -$908.6K -$924.7K $1.3M $120.4K

3. CUPR Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is CUPR stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, Cuprina Holdings (Cayman) Limited (Class A) (NASDAQ: CUPR) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 21/100 at a spot price of $1.84 (+3.96% 1D, market cap $13.5M). Pillar breakdown: Fundamental Cash Engine 3/20, Institutional 13F & Options Flow 3/20, SEC Balance-Sheet Forensics 3/20, FRED Macro Regime Fit 10/20, and Executive Insider Alignment 3/20. Across 1015 tracked Health Care issuers, CUPR ranks #972 in composite RQD confidence.

How does CUPR compare to CLGN and HSCS in the Health Care sector?

Within the Health Care sector (Industrial Specialties), CUPR carries a Roarable E (21/100 RQD), trailing P/E of N/A, gross margin of -1.3%, and ROIC of -35.0%. By comparison, CLGN (CollPlant Biotechnologies Ltd) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $11.9M) and HSCS (HeartSciences Inc.) posts a D- grade (38/100 RQD, P/E N/A, ROIC -35.0%, cap $16.0M). Among the 5-stock peer group, CUPR leads on earnings multiple (N/A) while CUPR leads on capital efficiency (-35.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for CUPR?

Per CUPR's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001995704), Cuprina Holdings (Cayman) Limited (Class A) generated $38.8K in revenue (+9.2% YoY), -$3.6M in net income, and -$7.1M in free cash flow against $6.6M in total assets and $98.1K in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately. Institutional options positioning shows a 50% call / 50% put premium split.

Where is CUPR trading relative to its 50-day, 200-day, and 52-week technical levels?

CUPR last traded at $1.84 (+3.96% on volume of 281,262 shares), positioning the stock -18.58% below its 50-day simple moving average ($2.26) and -38.67% below its 200-day simple moving average ($3.00). Across its 52-week range of $1.45 to $14.80, CUPR sits at the 2.9% percentile with a 14-day RSI of 41.1 (NEUTRAL RANGE) and an implied next-earnings move of Β±12.5% ($1.61 to $2.07).

Direct Sub-Reports: CUPR RQD Cockpit CUPR 12M Forecast CUPR Earnings & Move CUPR Dividends & DRIP CUPR Insiders & 13F CUPR Whale Options CUPR Profit Sankey CUPR News & Why
ROARABLE RATING BRIEF β€’ RQD 21/100 (E) βœ“ SEC XBRL & RQD VERIFIED

CUPR β€” Cuprina Holdings (Cayman) Limited (Class A): What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2025-12-31

1. Roarable Rating Brief: What This Means to a Prospective Investor

Cuprina Holdings (Cayman) Limited (Class A) (CUPR) earns a live Roarable RQD composite score of 21/100, corresponding to a E letter grade (Roarable Strong Sell) at a spot price of $1.84 (+3.96% 1D, market capitalization $13.5M).

  • Fundamental Cash Engine (3/20): Anchored by return on invested capital (ROIC) of -35.0%, gross margin of -1.3%, operating margin of -60.0%, and free cash flow yield of β€”.
  • Whale 13F & Options Flow (3/20) + Insider Conviction (3/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (10/20) + Forensic Balance Sheet (3/20): Incorporates a 1.00x equity beta, Altman Z-Score of 0.36, Piotroski F-Score of 3/9, and Debt/Equity of 0.02x.

2. Business Model, Unit Margins & SEC Financial Trajectory

Limited (Class A) trades on NASDAQ under ticker CUPR and is classified in the Health Care sector and Industrial Specialties industry. Per the financials, reported revenue is β€” in both FY 2025 and FY 2024. β€” for product lines, customer base, or revenue model.

In its latest audited SEC EDGAR 10-K filing for FY2025 (filed 2025-12-31), Cuprina Holdings (Cayman) Limited (Class A) (CUPR) reported $38.8K in annual revenue (up from $35.5K in FY2024, +9.2% YoY) and -$3.6M in GAAP net income. Over the multi-year SEC filing window from FY2024 ($35.5K revenue, -$1.1M net income) through FY2025, CUPR scaled operating cash flow to -$7.1M and free cash flow to -$7.1M, backed by $6.6M in total assets against $98.1K in total debt.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • πŸ‚ Primary Bull Case (E β€’ RQD 21/100): Established market leader in Health Care with deep daily trading liquidity. Free cash flow yield of β€” and institutional whale pillar of 3/20. With Fundamental Cash Engine at 3/20 and Institutional Whale Flow at 3/20, sustained execution supports upside toward the upper end of the $1.45 – $14.80 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Company executives have done more routine share selling than personal cash buying lately. Investors must weigh current valuation against -60.0% operating margins and a 1.00x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

β€” for upstream or downstream dependencies, sector correlations, or bottlenecks.

  • Key Question #1: Can CUPR sustain or expand its -60.0% operating margin and -35.0% ROIC against Industrial Specialties peers over the next 4 quarters?
  • Key Question #2: Following FY2025 revenue of $38.8K and free cash flow of -$7.1M, how will capital allocation balance growth reinvestment against $98.1K in total debt?
  • Key Question #3: How sensitive is CUPR's equity valuation to Health Care capital spending cycles and macro interest-rate shifts (Beta 1.00x)?

CUPR Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for Cuprina Holdings (Cayman) Limited (Class A) (CUPR) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to CUPR Debate Forum (3) ↓
🟑 MARKET WIRE Yahoo Finance β€’ 165d ago
Cuprina Holdings announces 1-for-8 Share Consolidation

SINGAPORE, May 22, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (β€œCuprina” or β€œthe Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medic

Read Full Source β†—
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

CUPR Bull vs. Bear Conversation Board β€” What's Your Call at $1.84?

πŸ‚ 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON CUPR 🐻 33% BEARISH CONVICTION
1. Pick Your Side on CUPR:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
MI MidwestValue RQD DEBATE OPENER β€’ Fundamental Long-Only πŸ‚ BULLISH 🎯 Target: $2.28 (+28.8%)
πŸ“Œ Pinned Debate

Cash on the balance sheet rose to $2.4M in FY 2025 with Debt/Equity at 0.02 per the RQD rating.

The street is overcomplicating Cuprina Holdings (Cayman) Limited (Class A) (CUPR). Cash on the balance sheet rose to $2.4M in FY 2025 with Debt/Equity at 0.02 per the RQD rating.. With an RQD score of 21/100 (E) and Forensic Balance Sheet at 2/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $1.91.

CapAlloc_Nerd πŸ‚ BULL

@MeanReversion_88 Fair point on current EV/EBITDA multiples, but you're ignoring the forward operating leverage in Industrial Specialties. If gross margin (-1.3%) holds, EPS grows into the multiple faster than bears think.

ME MeanReversion_88 RQD DEBATE OPENER β€’ Quantitative Statistical Arb 🐻 BEARISH 🎯 Target: $1.36 (-23.2%)
Spot @ $1.77

ROIC of -35% and an Altman Z-Score of 0.36 signal weak returns and forensic distress.

Careful chasing CUPR at $1.77. ROIC of -35% and an Altman Z-Score of 0.36 signal weak returns and forensic distress.. Gross margin is -1.3%, but operating margin is -60.0%, which shows SG&A and reinvestment are eating into bottom-line EPS. Target $1.36 on multiple compression.

LIVE TAPE